tetano
Editor, Senior Moderator
Open Forum Infect Dis
. 2021 Nov 3;8(12)
fab546.
doi: 10.1093/ofid/ofab546. eCollection 2021 Dec.
Bamlanivimab Efficacy in Older and High-BMI Outpatients With COVID-19 Selected for Treatment in a Lottery-Based Allocation Process
Emily B Rubin[SUP] 1 [/SUP], Jonathan A Boiarsky[SUP] 2 [/SUP], Lauren A Canha[SUP] 3 [/SUP], Anita Giobbie-Hurder[SUP] 4 [/SUP], Mofei Liu[SUP] 4 [/SUP], Matthew J Townsend[SUP] 5 [/SUP], Michael Dougan[SUP] 3 [/SUP]
Affiliations
Abstract
Background: Given the challenges associated with timely delivery of monoclonal antibody (mAb) therapy to outpatients with coronavirus disease 2019 (COVID-19) who are most likely to benefit, it is critical to understand the effectiveness of such therapy outside the context of clinical trials.
Methods: This was a case-control study of 1257 adult outpatients with COVID-19, ≥65 years of age or with body mass index (BMI) ≥35, who were entered into a lottery for mAb therapy.
Results: Patients who were called to be offered mAb therapy had a statistically significant 44% reduction in the odds of hospitalization within 30 days of a positive severe acute respiratory syndrome coronavirus 2 test compared with those who were not called (odds ratio [OR], 0.56; 95% CI, 0.36-0.89; P=.01). Patients who actually received bamlanivimab had a statistically significant 68% reduction in the odds of hospitalization compared with those who did not receive bamlanivimab (OR, 0.32; 95% CI, 0.11-0.93; P=.04).
Conclusions: This study supports the effectiveness of bamlanivimab in reducing COVID-19-related hospitalizations in patients ≥65 or with BMI ≥35.
Keywords: COVID-19; monoclonal antibodies.
. 2021 Nov 3;8(12)
fab546.doi: 10.1093/ofid/ofab546. eCollection 2021 Dec.
Bamlanivimab Efficacy in Older and High-BMI Outpatients With COVID-19 Selected for Treatment in a Lottery-Based Allocation Process
Emily B Rubin[SUP] 1 [/SUP], Jonathan A Boiarsky[SUP] 2 [/SUP], Lauren A Canha[SUP] 3 [/SUP], Anita Giobbie-Hurder[SUP] 4 [/SUP], Mofei Liu[SUP] 4 [/SUP], Matthew J Townsend[SUP] 5 [/SUP], Michael Dougan[SUP] 3 [/SUP]
Affiliations
- PMID: 34888396
- PMCID: PMC8651159
- DOI: 10.1093/ofid/ofab546
Abstract
Background: Given the challenges associated with timely delivery of monoclonal antibody (mAb) therapy to outpatients with coronavirus disease 2019 (COVID-19) who are most likely to benefit, it is critical to understand the effectiveness of such therapy outside the context of clinical trials.
Methods: This was a case-control study of 1257 adult outpatients with COVID-19, ≥65 years of age or with body mass index (BMI) ≥35, who were entered into a lottery for mAb therapy.
Results: Patients who were called to be offered mAb therapy had a statistically significant 44% reduction in the odds of hospitalization within 30 days of a positive severe acute respiratory syndrome coronavirus 2 test compared with those who were not called (odds ratio [OR], 0.56; 95% CI, 0.36-0.89; P=.01). Patients who actually received bamlanivimab had a statistically significant 68% reduction in the odds of hospitalization compared with those who did not receive bamlanivimab (OR, 0.32; 95% CI, 0.11-0.93; P=.04).
Conclusions: This study supports the effectiveness of bamlanivimab in reducing COVID-19-related hospitalizations in patients ≥65 or with BMI ≥35.
Keywords: COVID-19; monoclonal antibodies.